{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-23-000038","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.105054+00:00","generated_at":"2026-06-09T00:37:01.828478+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"AbCellera Q3 revenue plunges to $6.6M from $101M; net loss $0.10/sh vs prior year profit","bullets":["Total revenue $6.6M, down 93.5% from $101.4M in Q3 2022.","Net loss of $28.6M ($0.10 loss per share) vs net earnings of $26.6M ($0.09 EPS) in Q3 2022.","Cumulative partnered program starts reached 110, up 20% YoY; 10 molecules in clinic.","Two AbCellera-led programs advanced into IND-enabling studies.","Cash, cash equivalents, and marketable securities $813.0M; R&D expenses $37.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-23-000038","json":"https://secwatch.observer/filing/0001703057-23-000038.json","markdown":"https://secwatch.observer/filing/0001703057-23-000038.md","text":"https://secwatch.observer/filing/0001703057-23-000038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000038/0001703057-23-000038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000038/abcl-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:37:01.828478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a406cdb3cc6dfb0517a24256a45e95ebf50fe31d","claim":"AbCellera Biologics Inc. reported the quarter ended September 30, 2023 results: revenue $6.6 million, net income net loss of $28.6 million, EPS $(0.10) per share on a basic and diluted basis.","evidence_excerpt":"value, both through strategic partnerships, and through internal discovery and development of potential first-in-class antibody therapies.” Q3 2023 Business Summary ● Earned $6.6 million in total revenue. ● Generated a net loss of $28.6 million, compared to net earnings of $26.6 million in Q3 2022. ● Reached a cumulative total of 182 programs under contract with","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000038/0001703057-23-000038-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$6.6 million"},{"label":"Net income","value":"net loss of $28.6 million"},{"label":"EPS","value":"$(0.10) per share on a basic and diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}